Last reviewed · How we verify
Niferex
At a glance
| Generic name | Niferex |
|---|---|
| Also known as | MonoFer, iron polysaccharide, Polysaccharide Iron Complex |
| Sponsor | Qianfoshan Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.
Common side effects
Key clinical trials
- EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
- Efficacious Iron for Iron Deficiency Anemia in Adults Aged ≥18 Years (NA)
- Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in Pregnancy (PHASE4)
- Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia (PHASE4)
- Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients (PHASE3)
- Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia (PHASE4)
- Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niferex CI brief — competitive landscape report
- Niferex updates RSS · CI watch RSS
- Qianfoshan Hospital portfolio CI